StreetInsider.com Pre-Open Movers:

Point Therapeutics, Inc. (NASDAQ: POTP) 77% LOWER; The FDA has placed the clinical program for talabostat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE